Guggenheim reaffirmed their buy rating on shares of Maze Therapeutics (NASDAQ:MAZE - Free Report) in a research report released on Wednesday morning,Benzinga reports. Guggenheim currently has a $19.00 price target on the stock.
Other analysts have also issued research reports about the stock. Leerink Partners started coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They set an "outperform" rating and a $28.00 price objective for the company. Leerink Partnrs upgraded Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. JPMorgan Chase & Co. started coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They set an "overweight" rating and a $30.00 price objective on the stock. Finally, TD Cowen raised shares of Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 25th. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $25.67.
Check Out Our Latest Analysis on MAZE
Maze Therapeutics Stock Performance
Shares of NASDAQ MAZE traded down $0.25 during trading hours on Wednesday, reaching $9.07. The stock had a trading volume of 327,522 shares, compared to its average volume of 303,896. Maze Therapeutics has a twelve month low of $8.33 and a twelve month high of $17.00.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Monday, March 31st. The company reported ($18.32) EPS for the quarter, missing analysts' consensus estimates of ($7.60) by ($10.72).
Maze Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
See Also
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
